Tevogen Bio Holdings Inc.

Tevogen Bio Holdings Inc., trading under the ticker LGST, is a clinical-stage biopharmaceutical company focused on developing T-cell-based immunotherapies targeting infectious diseases and oncology. The company completed its SPAC business combination and began trading as a public entity in 2022, operating in the life sciences and biotechnology sector. Its quarterly report on Form 10-Q, filed with the SEC on November 14, 2022, under accession number 0001410578-22-003394, provides a financial and operational update covering the period following the de-SPAC transaction. For complete filing history, merger terms, and sponsor details on LGST, sign up for full data access at SpacDesk.